Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex Pharmaceuticals

492.42
+1.950.40%
Pre-market: 492.420.00000.00%08:16 EDT
Volume:1.25M
Turnover:613.93M
Market Cap:126.59B
PE:-236.74
High:498.41
Open:488.27
Low:484.97
Close:490.47
Loading ...

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

GlobeNewswire
·
06 Mar

TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
05 Mar

Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value

Simply Wall St.
·
05 Mar

Vertex Pharmaceuticals: Buy Rating Driven by Outpatient Market Potential and Strategic Initiatives for Journavx

TIPRANKS
·
05 Mar

Top Executive Makes Bold Move with Major Vertex Stock Purchase!

TIPRANKS
·
05 Mar

5 Top Stocks to Buy in March

Motley Fool
·
04 Mar

Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market

TIPRANKS
·
04 Mar

Vertex Is Maintained at Buy by Goldman Sachs

Dow Jones
·
03 Mar

Counterpart Health Partners with Google Cloud to Improve Clinical Data Access for Physicians

GlobeNewswire
·
03 Mar

Vertex, Inc. (VERX): Among the Worst Performing Software Stocks to Buy According to Analysts

Insider Monkey
·
03 Mar

Vertex, Inc. Faces Financial Turmoil Amid Potential ‘Fundamental Change’ Risks

TIPRANKS
·
01 Mar

Vertex Pharmaceuticals Inc. Stock Rises Friday, Still Underperforms Market

Dow Jones
·
01 Mar

Why Vertex, Inc. (VERX) Went Down on Thursday

Insider Monkey
·
28 Feb

Vertex shares down after Stifel downgrades stock to hold

Investing.com
·
28 Feb

Vertex price target lowered to $41 from $56 at BMO Capital

TIPRANKS
·
28 Feb

Vertex Is Maintained at Outperform by Baird

Dow Jones
·
28 Feb

Morgan Stanley Sticks to Their Buy Rating for Vertex (VERX)

TIPRANKS
·
28 Feb

Vertex Receives Chmp Positive Opinion for Expanded Label for Kaftrio® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations

THOMSON REUTERS
·
28 Feb

Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations

Business Wire
·
28 Feb

Ema's Chmp: Extending Therapeutic Indication of Kaftrio, Kalydeco for Cystic Fibrosis in Patients Aged 2 Yrs and Older With Certain Cftr Mutations

THOMSON REUTERS
·
28 Feb